Qualifying for ketamine treatment typically requires a documented history of conditions that haven’t responded to standard therapies, a medical screening to rule out safety risks, and in many cases, specific paperwork or program enrollment. The exact requirements depend on whether you’re pursuing the FDA-approved nasal spray (esketamine, brand name Spravato) or off-label IV ketamine infusions, which operate under different rules.
What Ketamine Is Approved For
Ketamine itself is only FDA-approved as an anesthetic. Its use for depression, chronic pain, anxiety, or PTSD is considered off-label, meaning a provider can legally prescribe it but it hasn’t gone through the formal approval process for those conditions. The one exception is Spravato, a nasal spray containing a close chemical relative of ketamine, which has FDA approval specifically for treatment-resistant depression and major depressive disorder with acute suicidal ideation in adults 18 and older.
This distinction matters because it shapes everything downstream: what your insurance will cover, what documentation you’ll need, and how structured the treatment process is.
The Core Qualifying Conditions
Most ketamine clinics and insurance plans focus on two main categories: mental health conditions and chronic pain.
For depression, the primary pathway is treatment-resistant depression. The clinical definition requires that at least two different antidepressants, taken at adequate doses for at least six to eight weeks each, failed to adequately control your symptoms during a depressive episode. Some insurance plans go further. Montana’s Medicaid criteria, which reflect common patterns across insurers, also require that you tried augmenting an antidepressant with an additional medication (an atypical antipsychotic approved for depression or lithium) and that you’re actively participating in psychotherapy or have documented that therapy alone was insufficient.
The second approved mental health pathway is major depressive disorder with active suicidal thoughts or behavior. This is a more acute scenario, and some insurers require that the first doses be administered in an inpatient setting with documented psychiatric assessment.
For chronic pain, ketamine may be considered for neuropathic pain conditions when more conservative treatments have failed. The American Society of Anesthesiologists acknowledges its use in this context, though specific qualifying diagnoses (complex regional pain syndrome, fibromyalgia, certain nerve injuries) vary by clinic and insurer. Pain-related ketamine is almost always off-label and often not covered by insurance.
Medical Conditions That Disqualify You
Ketamine raises blood pressure and heart rate, sometimes significantly. In studies of IV infusions for depression, roughly 20 to 30 percent of patients experienced blood pressure spikes above 180/100 or heart rates above 110 beats per minute during treatment, and some required medication to bring it back down. Because of this, uncontrolled hypertension and unstable cardiovascular disease are standard exclusion criteria. If your blood pressure is well-managed on medication, you may still qualify, but expect close monitoring.
Other conditions that typically disqualify you:
- History of psychosis. Ketamine can trigger dissociative and psychiatric events, making it unsafe for people with schizophrenia or a history of psychotic episodes.
- Increased intracranial pressure. Ketamine can raise pressure inside the skull, which is dangerous for people with certain neurological conditions.
- Aneurysmal vascular disease. This includes aneurysms in the aorta, brain, or peripheral arteries, as well as arteriovenous malformations or a history of bleeding in the brain.
- Current pregnancy.
- Previous negative response to ketamine. If you’ve had a bad reaction before, most clinics will not proceed.
Substance Use and Drug Screening
Active substance abuse, including alcohol, cannabis, and non-prescribed medications, is a standard exclusion. Ketamine itself is a Schedule III controlled substance with abuse potential, so clinics assess your risk for misuse before starting treatment and periodically throughout.
Many clinics require a urine drug screen before the first infusion and may repeat it during your treatment course. A history of past substance use disorder doesn’t automatically disqualify you if you’re currently in stable recovery, but active use typically does. Expect honest, direct questions about your substance use history during intake.
The Screening and Intake Process
Before your first treatment, you’ll go through a psychiatric and medical evaluation. On the psychiatric side, clinics use standardized depression rating scales (commonly the PHQ-9 or similar tools) to establish a baseline score for your symptoms. This baseline serves two purposes: it documents your current severity and creates a benchmark to measure whether the treatment is working at renewal time.
The medical evaluation focuses on cardiovascular health, current medications, neurological history, and the exclusion criteria listed above. For older adults, clinics apply additional screening for heart health, drug interactions, and metabolic function, though there is no strict upper age limit.
For Spravato specifically, both you and the prescribing facility must be enrolled in a mandatory safety program called REMS. Before your first dose, you’ll receive counseling about the risks of sedation and dissociation, then complete a formal enrollment form. This enrollment is verified before every single treatment session.
Age Requirements
The standard minimum age is 18 for both Spravato and most off-label ketamine clinics. Adolescents between 13 and 17 may occasionally access treatment at specialized clinics after standard therapies have failed, but this requires parental consent and close monitoring. Seniors in their 60s, 70s, and beyond can qualify as long as their cardiovascular and neurological health checks out, sometimes with adjusted dosing to account for slower metabolism and more medications.
What Insurance Requires for Spravato
If you’re pursuing the FDA-approved nasal spray, expect a prior authorization process. Your provider will need to submit clinical documentation showing you meet specific criteria. A typical insurance requirement includes all of the following: you’re 18 or older, you have a formal diagnosis of major depressive disorder, you have a recent depression score from a validated rating scale, you’re currently taking an oral antidepressant and will continue it alongside Spravato, and you meet the definition of treatment-resistant depression or have documented suicidal ideation.
For renewal, insurers want evidence that the treatment is working. That means showing a measurable reduction in your depression score compared to baseline, continued compliance with your oral antidepressant, and ongoing adherence to the treatment schedule.
Off-label IV ketamine infusions are rarely covered by insurance. Most patients pay out of pocket, with individual infusion sessions typically costing several hundred dollars each.
What Happens During Treatment Sessions
Whether you receive IV infusions or the nasal spray, every session takes place in a medical setting. You won’t receive ketamine to take at home through the REMS program. After each dose, you’re monitored for at least two hours for sedation, dissociation, and blood pressure changes. A monitoring form is completed and submitted after every session. You’ll need someone to drive you home, as you should not drive or operate machinery for the rest of the day.
The FDA has warned specifically about compounded ketamine products (versions mixed by specialty pharmacies, sometimes prescribed for at-home use), noting risks of sedation, respiratory depression, and psychiatric worsening that are harder to manage outside a clinical setting. If a provider offers you ketamine to use unsupervised at home, that falls outside the safety framework built around the approved product.